Aquestive Therapeutics, Inc.
As of Oct 22, 2026, Aquestive Therapeutics is in Stage 2, the uptrend phase, now in week 5 (since Sep 21, 2026). It closed at $4.13, 41.1% below its 52-week high and below its 200-day average, which is falling.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care
Is AQST early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AQST among Drug Manufacturers - Specialty & Generic56th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …56 | AQST | Stage 2 · wk 5 | 27 | −12.1% |
Aquestive Therapeutics: quick answers
What stage is Aquestive Therapeutics in?
As of Oct 22, 2026, Aquestive Therapeutics (AQST) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 21, 2026 and is in week 5. What the four stages mean
Is Aquestive Therapeutics in an uptrend?
Yes. Aquestive Therapeutics is in a Stage 2 uptrend. It trades 2.2% below its 200-day average, which is falling.
How far is Aquestive Therapeutics from its 52-week high?
Aquestive Therapeutics closed at $4.13 on Oct 22, 2026, 41.1% below its 52-week high of $7.02. Its 52-week low is $2.95.
How has Aquestive Therapeutics performed over the past year?
As of Oct 22, 2026, Aquestive Therapeutics is down 41.3% over the past year and down 36.0% so far in 2026.
Which sector and industry is Aquestive Therapeutics in?
Aquestive Therapeutics is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.